A New Era in Prostate Imaging
MRI has transformed how prostate cancer is detected and monitored. It allows many men to avoid unnecessary biopsies and stay safely on Active Surveillance. However, traditional MRI scans use contrast dye, which raises concerns about safety, cost, and comfort.
This session explored a simpler alternative: biparametric MRI (bpMRI) for prostate cancer— a faster, contrast-free scan that offers the same accuracy as the standard multiparametric MRI (mpMRI). By skipping contrast dye, bpMRI can make imaging safer, shorter, and more accessible for patients.
What the Research Shows
Dr. Veeru Kasivisvanathan presented results from the PRIME trial, showing that biparametric MRI performs just as well as contrast-enhanced imaging. Similarly, Dr. Matthew Davenport explained how avoiding gadolinium protects patients with kidney disease and reduces long-term risks. Finally, Dr. Benjamin Pockros shared Michigan’s early experience with bpMRI, where shorter scan times and lower costs have already improved access and patient satisfaction.
Together, these findings confirm that biparametric MRI for prostate cancer can match traditional imaging in accuracy while removing many barriers to care.
Why It Matters for Patients
Faster, safer imaging helps men on Active Surveillance remain confident in their monitoring plans. The speakers described how bpMRI, paired with new AI tools, may soon reshape prostate cancer care — offering precision without added risk.
bpMRI’s advantages include:
No contrast dye, reducing safety concerns
Shorter, more comfortable exams
Lower costs and easier scheduling
Comparable diagnostic accuracy to mpMRI
This new approach represents a significant step toward more accessible, patient-centered imaging.
Watch the Discussion
Chapters
00:00 – Welcome & introductions (Bill Manning: ASPI overview, disclaimers, format)
03:02 – Opening remarks (Mark Lichty & Howard Wolinsky: history, gadolinium concerns, speaker intros)
10:27 – Dr. Veeru Kasivisvanathan (UCL): PRIME trial results — bpMRI vs mpMRI
24:25 – Dr. Matthew Davenport (Michigan): gadolinium safety, retention, and contrast logistics
38:21 – Dr. Benjamin Pockros (Michigan): bpMRI adoption pilot, cost savings, and patient experience
50:56 – Panel Q&A: U.S. vs. U.K. access, radiology quality, and patient preparation
1:13:33 – Claustrophobia, comfort, and scan duration benefits
1:18:18 – Repeat scans, macrocyclic vs linear contrast agents, and safety over time
1:30:08 – AI in MRI: faster scans, diagnostic consistency, and global access
1:35:09 – Final Q&A and closing discussion
About Our Speakers
Dr. Veeru Kasivisvanathan is a consultant urologist and senior lecturer at University College London. He leads several international studies, including the PRIME and PRECISION trials, which redefined MRI-guided diagnosis. His research focuses on accuracy, overtreatment reduction, and expanding MRI access.
Dr. Matthew Davenport is a professor of radiology and urology at the University of Michigan. An authority on MRI safety and contrast media, he has authored national guidelines on imaging quality, kidney risk, and gadolinium retention.
Dr. Benjamin Pockros is a urology resident and researcher at the University of Michigan. His work focuses on integrating biparametric MRI into everyday care, showing how faster, simpler protocols can make prostate cancer imaging more equitable.
Learn More
- Check out our short videos on biparametric MRI for prostate cancer here.